Introduction {#Sec1}
============

The World Health Organization determined that patients aged 80 years or more will number approximately 400 million by 2050 \[[@CR1]\]. In Europe, the elderly population (\> 65 years old) is estimated to approach 28.5% in 2050 compared to 19.2% in 2016 \[[@CR2]\]. The aging population correlates with an increasing prevalence of aortic valve disease, primarily aortic stenosis (AS). Thus, it is anticipated that in the future greater numbers of elderly patients will require aortic valve replacement (AVR). From 1999 to 2011, the rate of AVR per 100,000 person-year increased, with a significant increment in patients \> 75 years old \[[@CR3]\].

Among elderly patients referred for AVR, the rate of coronary artery disease (CAD) ranges between 40 and 70% \[[@CR3]--[@CR5]\], and approximately one-half of patients require coronary artery bypass grafting (CABG) in addition to AVR \[[@CR6]\]. Medical therapy cannot improve patients with symptomatic aortic valve disease, and surgical AVR remains the gold standard for patients with low and intermediate operative risk. It is strongly recommended that concomitant CABG is performed at the time of AVR for critical (\> 70%) coronary stenosis \[[@CR6]\].

Transcatheter aortic valve implantation (TAVI) provides an option for elderly and high-risk patients who otherwise may be excluded from conventional surgical AVR. In intermediate-risk patients, TAVI has lower 30-day mortality and stroke reported compared to conventional AVR \[[@CR7]\]. Although TAVI results to date are encouraging, there remain significant limitations. The procedure is technically demanding, especially in the setting of aggressive peripheral arteriopathy. Furthermore, significant noteworthy complications, such as perivalvular leak, requirement for permanent pacemaker implantation, acute kidney injury, and embolic stroke remain concerns \[[@CR8]\].

While early and late results in elderly patients undergoing isolated AVR are homogeneous, the early and late outcomes of combined AVR with CABG are still unclear and sometimes conflicting. In elderly patients, AVR with CABG has been reported to be associated with early mortality ranging from 1.9 to 24% \[[@CR9]--[@CR12]\] compared to AVR alone (ranging from 0 to 7.6%) \[[@CR13]--[@CR17]\]. In the overall population, simultaneous AVR and CABG have worse long-term survival compared to isolated AVR \[[@CR18]\], while among the elderly population, survival between the two treatments appears to be comparable \[[@CR19]--[@CR21]\].

This study sought to investigate whether combined AVR and CABG increases early mortality and morbidity and long-term survival compared with isolated AVR in elderly patients aged more than 75 years.

Materials and methods {#Sec2}
=====================

Retrospective evaluation of prospectively collected data from the local surgery database at the San Gerardo Hospital, University of Milano-Bicocca (Monza, Italy), was conducted. From June 1, 1999, to Jun 31, 2018, 1284 patients underwent isolated AVR (iAVR) or AVR combined with other cardiac surgical procedures. 402 elderly (≥ 75 years) patients underwent iAVR or combined with CABG. Figure [1](#Fig1){ref-type="fig"} shows both the total number of patients and the patients of the study population operated year by year during the study period. The subjects were divided into two groups according to the type of the operation: iAVR group (*n* = 200; 49.7%) and AVR + CABG group (*n* = 202; 50.3%). Patients who underwent emergency or salvage operation were excluded from the analysis. All patients were examined with two-dimensional and Doppler echocardiography and coronary angiogram. The local ethical committee approved the Myocardial REvascularization associated with Aortic valve replacement in the Long-TERM survival in the elderly population (My-REALTERM) study. Individual patient consent was waived (EC resolution n. 1560, 17th October 2017). Primary study end points were early and late all-cause mortality.Fig. 1Upper panel: year-by-year trend of all patients who underwent isolated aortic valve replacement or combined with other cardiac procedure. Lower panel: year-by-year trend of all patients included in the study population

Variable definitions {#Sec3}
--------------------

All variables included in the EuroSCORE II model were included. Atrial fibrillation was divided into paroxysmal or persistent/permanent. Urgent operations were procedures performed in patients whose symptoms dramatically worsened, or stable patients with severe coronary anatomy, or haemodynamically unstable patients requiring inotropes. Urgent operations were performed during the same hospital stay as the referral.

All patients underwent preoperative coronary angiogram and echocardiography. Left main disease was defined as stenosis greater than 50%. Critical coronary disease was defined as stenosis greater than 70%, or more the 60% in the proximal left anterior descending artery.

Regarding perioperative variables, stroke was defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction that occurred in the perioperative or postoperative period with symptoms remaining evident for more than 24 h and with imaging evidence of brain infarction. Transient ischemic attack (TIA) was defined as a transient neurological event with loss of neurological function during less than 24 h. Perioperative myocardial infarction was defined if two of the three following signs were simultaneously recorded within 72 h after the operations: new Q-waves on electrocardiography, new hypokinesia or akinesia myocardial segments at echocardiogram or abnormal release of creatine kinase MB more than five times the upper limit of normal value (25 IU/l). Low cardiac output syndrome was defined as the need for inotropes and or intra-aortic balloon pump. Respiratory failure was defined as the need for prolonged mechanical ventilation more than 48 h or the requirement of tracheostomy. Major adverse cardiovascular and cerebral events (MACCE) were defined as operative mortality, stroke, new myocardial infarction and acute renal failure. Re-intervention was defined as an operation during the same hospital stay because of postoperative bleeding or cardiac tamponade. Operative mortality was defined as any death occurring within 30 days from the time of surgery if the patients had been discharged from the hospital, or any death occurring during the initial hospital stay regardless of the time from the operation.

Surgical technique {#Sec4}
------------------

All patients received standard anaesthesia. Median sternotomy was performed and cardiopulmonary bypass (CPB) established through ascending aorta and right atrial cannulation. Heparin was administered to achieve an activated clotting time \> 480 s during CPB. The heart was arrested with intermittent antegrade and retrograde cold blood cardioplegia. In patients undergoing AVR + CABG, circumflex marginal branches and right coronary artery distal coronary anastomoses were performed prior to AVR. The left internal thoracic artery was grafted to the left anterior descending artery following AVR. Proximal anastomoses were performed following aortotomy closure. We approached the aortic valve most commonly through a transverse aortotomy.

Aortic valve prosthesis selection was based on patient age, and patient or surgeon preference. The prosthetic valves were placed in a supra or infra-annular position according to the size of the annulus and the type of prosthesis.

Postoperatively, warfarin therapy was administered regardless of the type of aortic valve prosthesis implanted, unless there were specific contraindications to the use of warfarin. This was administered with a therapeutic international normalized ratio (INR) target between 2.0 and 3.0. Those patients who underwent the implantation of a bioprosthesis were switched over from warfarin therapy to 100 mg of aspirin therapy at 3 months postoperatively, unless warfarin therapy was indicated postoperatively for persistent postoperative atrial fibrillation.

Statistical analysis {#Sec5}
--------------------

Categorical data were expressed as percentages; continuous data were expressed as mean ± SD. Differences between iAVR and AVR + CABG groups were compared with *X*^2^ statistical test for categorical variables and *T* test for continuous variables. To measure the treatment effect, odds ratios for binary and differences of means for continuous end points were calculated. Univariate and stepwise multivariate logistic regression analysis were performed to identify independent predictors of operative mortality and MACCE. A significance level of *p* \< 0.25 was used to enter variables into multivariate backward stepwise logistic regression analysis. A bootstrap technique (1000 resampling and respective multivariate analysis) was used for internal validation, and area under the curve (AUC) of the receiver operative characteristic (ROC) curves of both logistic regression and bootstrap were analysed to validate the model. Results are reported as percentages and odd ratio (OR) with 95% confidence intervals.

Long-term outcome was defined by all-cause mortality. This is an objective, unbiased end point, avoiding inaccurate, unsystematic and biased data derived from clinical documentation or medical data \[[@CR22]\]. Death information was obtained from the Regional Institutional Health Database System for all patients. Long-term follow-up was calculated for patients who survived surgery and were discharged, from the time of operation to death or last follow-up. Follow-up was closed on November 17, 2018. Overall survival was estimated by the Kaplan--Meier method and expressed as percentage. The difference between the survival curves was assessed using log-rank test. To identify independent predictors of late mortality, univariate and multivariate Cox proportional hazards models were constructed. Covariates included in the model were determined a priori and included all the preoperative variables. A significance level of *p* \< 0.25 was used to enter variables in the Cox regression analysis. Due to differences in underlying patient characteristics, propensity matching of iAVR with AVR + CABG patients was employed. A propensity score (PS) was calculated and the resulting PS for each patient represented the probability of being in the iAVR or in the AVR + CABG group. Pretreatment variables were compared using the standardized mean difference (SMD) and a high quality of the matching was considered when the covariate balance between the groups showed an SMD less than 10%. To neutralize the adverse effect of coronary artery disease, this covariate was not entered in the multivariable logistic regression model. Survival was compared for propensity-matched patients using the stratified log-rank test. All *p* values \< 0.05 were considered statistically significant. All statistical analysis was performed using SPSS v.25.0 (Statistical Package for Social Science, SPSS Inc. Chicago, IL, USA) and Stata/MP 15.1 (Stata, Corp College Station, TX, USA).

The performance of EuroSCORE II model was evaluated analysing the discrimination power and calibration. The discrimination indicates how well the model separates patients who will die or survive at 30 days after surgery. Discrimination was evaluated by constructing a receiver operative characteristic (ROC) curves and calculating the area under the curve (c-statistic) with 95% confidence intervals (CI).

Calibration was evaluated by generating a calibration plot by quintile of scores for operative mortality that compare the prediction with the observed probability. The Fisher exact test was used to compare the observed and predicted operative mortality. Calibration was tested with the Hosmer--Lemeshow goodness-of-fit test which compares observed to predicted values by decile of predicted probability. Furthermore, the validity of the model was tested by calculating the Brier score, whose value is 0 when the prediction is perfect.

Results {#Sec6}
=======

The study population included 402 subjects stratified by treatment and divided into two groups: iAVR, *n* = 200, and AVR + CABG, *n* = 202. Demographic data and preoperative variables are outlined in Table [1](#Tab1){ref-type="table"}. The overall mean age was 78 ± 2.7 years, while AVR + CABG patients were older than iAVR patients (78.5 vs 77.6 years, respectively; *p* \< 0.0001). Patients undergoing combined AVR and CABG were also more likely males, with more baseline comorbidities such as elevated blood glucose level, peripheral artery disease, advanced New York Heart Association class and Canadian Cardiovascular Society class 4, more recent myocardial infarction, more urgent operation and higher EuroSCORE II. The iAVR group had higher ejection fractions (56.7% vs 54%, respectively; *p* = 0.028), greater aortic peak gradients (81.8 mmHg vs 73.3 mmHg, respectively; *p* = 0.002), and greater aortic mean gradients (51.4 mmHg vs 45.4 mmHg, respectively; *p* = 0.002). No differences were observed in aortic valve area, grade of myocardial hypertrophy, pulmonary artery pressure and mitral valve regurgitation grade (Table [2](#Tab2){ref-type="table"}). In our institution, the TAVI program started in 2009. To verify whether any differences were reported among the patients during the study period, the study population was divided into two groups: pre-TAVI era (1999--2008; *n* = 154) and post-TAVI era (2009--2018; *n* = 248). Table [3](#Tab3){ref-type="table"} reports some outcome and characteristics between the two eras. Among the variables analysed, we have observed a significant higher number of patients with EuroSCORE II ≥ 15% in patients of the 2009--2018 era (*p* = 0.02), while the incidence of 30-day mortality and MACCE were comparable between the two eras.Table 1Preoperative variablesVariableAll patients (*n* = 402)iAVR (*n* = 200)AVR + CABG (*n* = 202)*p*Age78.1 ± 2.777.6 ± 2.578.5 ± 2.8\< 0.001Male (%)193 (48)77 (38.5)116 (57.4)\< 0.001Age ≥ 80 years (%)119 (29.6)52 (26)67 (33.2)0.11Weight (kg)69.8 ± 12.969.5 ± 13.170.1 ± 12.80.64Height (cm)164.4 ± 8.5163.3 ± 8.8165.5 ± 80.009BSA (m^2^)1.74 ± 0.191.73 ± 0.191.75 ± 0.180.18BMI25.7 ± 426 ± 425.5 ± 3.90.24BMI ≥ 30 (%)56 (13.9)30 (15)26 (12.9)0.53Hypertension (%)328 (81.6)162 (81)166 (82.2)0.76Dyslipidaemia (%)189 (47)79 (39.5)110 (54.4)0.003Diabetes (%)94 (23.4)45 (22.5)49 (24.3)0.67Diabetes on insulin (%)29 (7.2)10 (5)19 (9.4)0.08Glucose106 ± 34101.3 ± 29.1112.5 ± 38.80.001Smoke98 (24.4)42 (21)56 (27.7)0.11Atrial fibrillation0.88 *Paroxysmal (%)*36 (9)17 (8.5)19 (9.4) *Persistent/permanent*32 (8)17 (8.5)15 (7.4)Creatinine1.08 ± 0.581.03 ± 0.481.12 ± 0.670.14Creatinine ≥ 2 mg/dl (%)15 (3.7)8 (4)7 (3.5)0.77Creatinine clearance55.8 ± 18.656.9 ± 19.354.7 ± 17.90.24Creatinine clearance severe \< 50 ml/min (%)155 (38.6)70 (45.2)85 (54.8)0.14Dialysis (%)4 (1%)2 (1)2 (1)0.91Haemoglobin (g/dl)12.5 ± 1.712.4 ± 1.712.6 ± 1.70.33Peripheral arteriopathy (%)113 (28.1)39 (19.5)74 (36.6)\< 0.001Poor mobility (%)14 (3.5)7 (3.5)7 (3.5)0.98CVE (%)32 (8)14 (7)18 (8.9)0.47Previous cardiac operation (%)12 (3)9 (4.5)3 (1.5)0.07Previous CABG (%)7 (1.7)6 (3)1 (0.5)0.05Previous iAVR (%)3 (0.7)2 (1)1 (0.5)0.81Previous AVR + CABG (%)1 (0.2)0 (0)1 (0.5)0.75Previous other cardiac operation (%)2 (0.5)1 (0.5)1 (0.5)0.99COPD (%)54 (13.4)28 (14)26 (12.9)0.74Active endocarditis (%)10 (2.5)4 (2)6 (3)0.53NYHA class2.14 ± 0.772.03 ± 0.712.25 ± 0.810.004NYHA class 3--4 (%)106 (26.4)42 (21)64 (31.7)0.01CCS 4 (%)29 (7.2)4 (2)25 (6.2)\< 0.001Ejection fraction, %55.4 ± 10.656.7 ± 9.354 ± 11.60.01Ejection fraction ≤ 50% (%)98 (24.4)38 (38.8)60 (61.2)0.01Recent myocardial infarction (%)19 (4.7)2 (1)17 (8.4)\< 0.001PAPs ≥ 50 mmHg (%)42 (10.4)24 (12)18 (8.9)0.31Urgency operation (%)38 (9.5)6 (3)32 (15.8)\< 0.001Critical preoperative state (%)6 (1.5)1 (0.5)5 (2.5)0.10EuroSCORE 25.4 ± 5.83.6 ± 3.77.2 ± 6.9\< 0.001EuroSCORE 2 \> 15% (%)24 (6)5 (2.5)19 (9.4)0.003Aortic bicuspid valve (%)7 (1.7)5 (2.5)2 (1)0.24Aortic valve disease0.008 *Stenosis (%)*301 (74.9)150 (75)151 (74.8) *Insufficiency (%)*22 (5.5)16 (8)6 (3) *Both stenosis and insufficiency (%)*79 (19.7)34 (17)45 (22.3)Aetiology of valve disease0.05 *Degenerative (%)*321 (79.8)160 (80)161 (80.5) *Rheumatic (%)*51 (12.7)20 (10)21 (10.4)* Endocarditis, active or chronic (%)*22 (5.5)16 (8)6 (3) Other (%)8 (2)5 (2.5)3 (1.5)No. of vessel disease1.9 ± 0.8Left main disease (%)32 (15.8)1 vessel (%)70 (34.7)2 vessels (%)70 (34.7)3 vessels (%)62 (30.7)*iAVR* isolated aortic valve replacement, *CABG* coronary artery bypass grafting, *BSA* body surface area, *BMI* body mass index, *CVE* cerebrovascular events, *NYHA* New York Heart Association, *COPD* chronic obstructive pulmonary disease (under long-term use of bronchodilators or steroids), *CCS* Canadian Cardiovascular Society, *PAP* pulmonary systolic arterial pressureTable 2Preoperative echocardiogram dataVariableAll patients (*n* = 402)iAVR (*n* = 200)AVR + CABG (*n* = 202)*p*EF (%)55.4 ± 10.656.7 ± 9.354.1 ± 11.60.01Aortic peak gradient (mmHg)77.6 ± 25.581.8 ± 25.973.3 ± 24.50.002Aortic mean gradient (mmHg)48.5 ± 1751.4 ± 16.945.4 ± 16.70.002Aortic valve area (cm^2^)0.8 ± 0.270.78 ± 0.260.81 ± 0.290.39Aortic valve area index (cm^2^ /m^2^)0.46 ± 0.160.46 ± 0.150.47 ± 0.160.94Systolic septum wall thickness (cm)1.44 ± 0.311.46 ± 0.321.41 ± 0.280.19Aortic valve regurgitation (grade)1.11 ± 11.12 ± 1.111.15 ± 0.980.80PAP (mmHg)37.8 ± 11.738.7 ± 12.436.7 ± 10.80.16Mitral valve regurgitation (grade)1.2 ± 0.61.1 ± 0.61.2 ± 0.60.27*iAVR* isolated aortic valve replacement, *CABG* coronary artery bypass grafting, *EF* ejection fraction, *PAPs* pulmonary systolic arterial pressureTable 3Outcomes according two different erasVariablesEra 1999--2008 (*n* = 154)Era 2009--2018 (*n* = 248)*p*Age78.3 ± 2.877.9 ± 2.60.09Over 80 years, *n* (%)49 (31.8)70 (28.2)0.44Male, *n* (%)66 (42.9)127 (51.2)0.10EuroSCORE II4.76 ± 4.975.86 ± 6.330.05EuroSCORE II ≥ 15%, *n* (%)4 (2.6)20 (8.1)0.0230-day mortality, *n* (%)6 (3.9)16 (6.5)0.27MACCE, *n* (%)15 (9.7)26 (10.5)0.81iAVR77 (50)123 (49.6)0.93*iAVR* isolated aortic valve replacement, *MACCE* major adverse cerebral cardiovascular events

Perioperative data and early outcome {#Sec7}
------------------------------------

The operative data are outlined in Table [4](#Tab4){ref-type="table"}. As expected, aortic cross clamping (X-Clamp) time and cardiopulmonary bypass (CPB) time were significantly longer in AVR + CABG compared to iAVR subjects (*p* \< 0.0001). Bioprosthetic valves were implanted in over 92% of patients in both groups. The most common valve size was 23 mm (39% in iAVR group and 41.6% in AVR + CABG group). No difference was reported in the mean prosthesis size and mean prosthesis effective orifice area (EOA) between groups. Moderate patient--prosthesis mismatch (PPM), defined as EOA index \> 0.85 or \< 0.65 cm^2^/m^2^, was reported in 8.7% of all subjects, without any difference between groups. The AVR + CABG group underwent a mean of 1.9 ± 0.8 distal anastomoses and 171 of 202 patients (84.6%) had complete myocardial revascularization. 157 (77.7%) underwent left internal thoracic artery to left anterior descending coronary artery anastomosis.Table 4Perioperative variablesVariablesAll patients (*n* = 402)AVR (*n* = 200)AVR + CABG (*n* = 202)*p*Cardiopulmonary time (min)125.3 ± 39.4107.6 ± 26.8143.4 ± 41.9\< 0.001Aortic cross-clamp time (min)94.7 ± 29.879.7 ± 18.8110 ± 31.3\< 0.001Number of distal anastomoses1.9 ± 0.8Type of prosthesis0.32 *Mechanical (%)*21 (5.2)13 (6.5)8 (4) *Biological stented (%)*381 (94.8)187 (93.5)194 (96)Mean prosthesis EOA (cm^2^/m^2^)1.76 ± 0.271.76 ± 0.271.76 ± 0.260.94iEOA (cm^2^/m^2^)1.01 ± 0.151.02 ± 0.151.01 ± 0.140.50PPM grade0.60 *Normal (PPM \> 0.85 cm*^*2*^/*m*^*2*^)*(%)*366 (91.3)184 (92)182 (90.5) *Moderate (PPM 0.65--0.85 cm*^*2*^/*m*^*2*^)*(%)*35 (8.7)16 (8)19 (9.5)Mean prosthesis size22.4 ± 1.822.3 ± 1.822.6 ± 1.80.17 *Size 18 (%)*1 (0.2)1 (0.5)0 (0) *Size 19 (%)*28 (7)14 (7)14 (6.9) *Size 21 (%)*137 (34.6)74 (37)63 (31.2) *Size 23 (%)*162 (40.3)78 (39)84 (41.6) *Size 25 (%)*59 (14.7)27 (13.5)32 (15.8) *Size 27 (%)*15 (3.7)6 (3)9 (4.5)LAD territory target (%)156 (77.2)Diagonal branch (%)20 (10)Circumflex territory target (%)109 (54)RCA territory target (%)88 (43.6)LITA use (%)157 (77.7)LITA on LAD (%)156 (77.2)BITA (%)7 (3.5)RA use (%)4 (2)CMR (%)171 (84.7)*iAVR* isolated aortic valve replacement, *CABG* coronary artery bypass grafting, *iEOA* indexed effective orifice area, *PPM* prosthesis-patient mismatch, *LAD* left anterior descending, *RCA* right coronary artery, *LITA* left internal thoracic artery, *BITA* bilateral internal thoracic arteries, *RA* radial artery, *CMR* complete myocardial revascularization

Operative mortality occurred in nine patients (4.5%) in the iAVR group and in 13 patients (6.5%) in the AVR + CABG group. The difference was not statistically significant (*p* = 0.38). Overall operative mortality was 5.5%. Compared to the iAVR group, patients who underwent AVR + CABG needed more prolonged ventilator support (16.8% vs 7.5%; *p* = 0.004), required intra-aortic balloon pump support (4% vs 0%; *p* = 0.004), and suffered from low cardiac output syndrome (11.4% vs 4.5%; *p* = 0.011) and new myocardial infarction (3.5% vs 0.5; *p* = 0.03). Moreover, MACCE was present more in the AVR + CABG group (16.8% vs 8%, respectively; *p* = 0.007). Table [5](#Tab5){ref-type="table"} shows the early outcomes.Table 5Postoperative variablesVariablesAll patients (*n* = 402)iAVR (*n* = 200)AVR + CABG (*n* = 202)*p*Ventilator support ≥ 48 h (%)49 (12.2)15 (7.5)34 (16.8)0.004Tracheostomy (%)4 (1)1 (0.5)3 (0.7)0.32Intensive care unit stay (days)2.9 ± 5.82.7 ± 63.2 ± 5.70.41Re-exploration for bleeding (%)24 (6)14 (7)10 (5)0.38Neurologic injury13 (3.2)4 (2)9 (4.5)0.16Acute renal failure (%)30 (7.5)12 (6)18 (8.9)0.17Haemodialysis (%)9 (2.2)6 (3)3 (1.5)0.30LCO syndrome (%)32 (8)9 (4.5)23 (11.4)0.01Sepsis (%)21 (5.2)9 (4.5)12 (5.9)0.51Acute lung injury (%)24 (6)13 (6.5)11 (5.4)0.65Pneumonia (%)16 (4)5 (2.5)11 (5.4)0.13Multi-organ failure (%)8 (2)3 (1.5)5 (2.5)0.48Myocardial infarction (%)8 (2)1 (0.5)7 (3.5)0.03Endocarditis3 (0.7)1 (0.5)2 (1)0.56Atrial fibrillation (%)183 (45.5)95 (47.5)88 (43.6)0.42Required permanent PM (%)12 (3)8 (4)4 (2)0.23IABP (%)8 (2)0 (0)8 (4)0.004MACCE (%)50 (12.4)16 (8)34 (16.8)0.007Hospital stay10 ± 8.99.4 ± 8.710.7 ± 8.70.1530-day mortality (%)22 (5.5)9 (4.5)13 (6.5)0.38*iAVR* isolated aortic valve replacement, *CABG* coronary artery bypass grafting, *LCO* low cardiac output, *PM* pace-maker, *IABP* intra-aortic balloon pump, *MACCE* major adverse cerebral cardiovascular events

Multivariate analysis identified EuroSCORE II \[odd ratio (OR) 1.13; 95% confidence intervals (CI) 1.01--1.26; *p* = 0.015\], postoperative stroke (OR 12.53; 95% CI 1.19--131.13; *p* = 0.035), postoperative low cardiac output syndrome (OR 8.72; 95% CI 2.45--30.99; *p* = 0.001) and postoperative mechanical ventilation \> 48 h (OR 8.92; 95% CI 2.65--30.01; *p* \< 0.0001) as independent predictors of 30-day mortality. Treatment was not an independent predictor of 30-day mortality (Table [6](#Tab6){ref-type="table"}). The areas under the curves were 0.88 (95% CI 0.81--0.91; *p* = 0.002) and 0.89 (95% CI 0.82--0.92; *p* = 0.002) for the logistic regression model and the bootstrap validation model, respectively.Table 6Multivariate analysis for 30-day mortality and in-hospital MACCEVariablesOdd ratio95% CI*p* value**Multivariate for 30-day mortality**EuroSCORE II1.131.01--1.260.01Postoperative stroke12.521.19--131.130.03Low cardiac output8.722.45--30.990.001Mechanical ventilation \> 48 h8.922.65--30.01\< 0.001Treatment (AVR + CABG)1.050.2--4.670.94**Multivariate for in-hospital MACCE**Preoperative CVE3.431.13--10.530.03Creatinine (mg/dl)7.272.46--21.50\< 0.001Cardiopulmonary bypass time1.011.004--1.0330.01Treatment (AVR + CABG)1.000.37--2.660.98*CVE* cerebrovascular events, *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting, *MACCE* major adverse cerebral cardiovascular event

Multivariate analysis identified preoperative cerebrovascular events (OR 3.43; 95% CI 1.13--10.53; *p* = 0.029), creatinine (OR 7.27; 95% CI 2.46--21.50; *p* \< 0.0001) and CPB time (OR 1.01; 95% CI 1.004--1.33; *p* = 0.011) as independent predictors of in-hospital MACCE. Again, treatment was not an independent predictor of in-hospital MACCE (Table [6](#Tab6){ref-type="table"}).

The area under the curve showed that the EuroSCORE model had a moderate discrimination power to predict the 30-day mortality with a *c*-statistic value of 0.73 (95% CI 0.631--0.831) (Fig. [2](#Fig2){ref-type="fig"}a). Calibration plot by quintile of EuroSCORE II for 30-day mortality showed that for each quintile risk profile, the EuroSCORE II performed well (Fig. [2](#Fig2){ref-type="fig"}b). Discrimination and calibration analysis are shown in Table [7](#Tab7){ref-type="table"}.Fig. 2**a** Calibration of 30-day mortality observed and predicted quintiles of EursoSCORE II. **b** Area under the curve for the EuroSCORE IITable 7Discrimination and calibration analysis for 30-day mortalityOutcomesPredicted 30-day mortality (EuroSCORE II)5.4 ± 5.8**Discrimination for 30-day mortality**C-statistic (95%, CI)0.73 (0.631--0.831)**Calibration for 30-day mortality (4%)**Observed/predicted ratio0.74Brier score0.05Fisher's exact test *p* value0.83Hosmer--Lemeshow test *p* value (Chi square)0.43 (8.02)

PS matching generated 138 matched pairs of patients. Figure [3](#Fig3){ref-type="fig"} shows the balancing covariates before and after propensity score matching. Between the iAVR and AVR + CABG group, postoperative outcome in terms of re-exploration for bleeding (8% vs 4.3%; 0.21), neurological adverse events (1.4% vs 1.4%; *p* \> 0.99), acute renal failure (4.3% vs 5.1%; *p* = 0.77), intensive care unit stay (2.1 ± 4.8 days vs 2.7 ± 5.2 days; *p* = 0.33), hospital stay (8.9 ± 6.9 days vs 9.6 ± 7.3 days; *p* = 0.33), atrial fibrillation (47.1% vs 41.3%; *p* = 0.33) and 30-day mortality (2.9% vs 5.1%; *p* = 0.35) were comparable. IABP support (0% vs 2.9%; *p* = 0.04) and ventilator support ≥ 48h (5.1% vs 11.6%; *p* = 0.05) were more represented in iAVR patients. The early outcome between matched and unmatched populations was similar.Fig. 3Love plot showing balancing covariates before and after propensity score matching. *CCS* Canadian Cardiovascular Society, *NYHA* New York Heart Association, *AMI* acute myocardial infarction, *AF* atrial fibrillation, *PAPs* pulmonary artery systolic pressure, *BMI* body mass index

Long-term results {#Sec8}
-----------------

Three-hundred and eighty (94.5%) patients survived hospital discharge beyond 30 days. Follow-up was achieved in 100% of patients with a median follow-up of 8.08 (95% CI 7.42--8.81) years, to a maximum of 16.1 years. Total follow-up had 6472 patient-years: 2914 patient-years for iAVR and 3252 patient-years in the AVR + CABG group.

One-hundred and eighty-six patients died at study completion (48.9%), with a mean survival of 7.9 ± 0.3 years, and median survival time of 8.08 (95% CI 7.42--8.81) years. The median follow-up time for iAVR was 8.20 (95% CI 7.56--8.81) years, with 108 patients (54%) still alive. The median follow-up time for AVR + CABG was 7.91 (95% CI 6.73--9.39) years with 108 patients (53.4%) still alive.

Survival at 1, 5 and 10 years was 94.7 ± 1.6%, 72.6 ± 3.6% and 31.7 ± 4.8% for patients included in the iAVR group and 89.1 ± 2.3%, 73.9 ± 3.5% and 37.2 ± 4.8% for patients who underwent AVR combined with CABG. Long-term survival curves are shown in Fig. [4](#Fig4){ref-type="fig"}a. Log-rank test did not reveal any significant difference between groups (*p* = 0.99). Moreover, matched survival was similar between the two groups and the trend of matched survival curves was comparable with the unmatched population (Fig. [4](#Fig4){ref-type="fig"}b).Fig. 4**a** Kaplan--Meier event-free-survival analysis for all-cause of death for all patients who survived the operation. *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting. **b** Kaplan--Meier event-free-survival analysis for all-cause of death in matched patients who survived the operation. *AVR* aortic valve replacement, *CABG* coronary artery bypass grafting

In Cox proportional hazard analysis, unadjusted concomitant AVR and CABG was not a predictor of late mortality \[hazard ratio (HR) 0.99; 95% CI 0.74--1.33; *p* = 0.99\]. Using adjusted multivariate analysis, creatinine (HR 1.50; 95% CI 1.07--2.10; *p* = 0.018), COPD (HR 1.97; 95% CI 1.26--3.08; *p* = 0.003) and NYHA class (HR 1.39; 95% CI 1.530--7.816; *p* \< 0.0001) were independent predictors of late mortality; the combined AVR + CABG was not associated with increased risk of late mortality (HR 0.83; 95% CI 0.59--1.17; *p* = 0.30) (Table [8](#Tab8){ref-type="table"}).Table 8Cox proportional hazard analysis for long-term mortalityVariablesHazard ratio95% CI*p* value**Unadjusted**Treatment (AVR + CABG)0.990.74--1.330.99**Adjusted**Creatinine (mg/dl)1.501.07--2.1000.01COPD1.971.26--3.080.003NYHA class1.391.05--1.830.01Treatment (AVR + CABG)0.830.59--1.170.30*AVR* aortic valve replacement, *CABG* coronary artery bypass grafting, *COPD* chronic obstructive pulmonary disease (under long-term use of bronchodilator or steroids), *NYHA* New York Heart Association

Discussion {#Sec9}
==========

Despite AVR + CABG patients being older than iAVR patients with greater comorbidity burden, and higher incidence of postoperative complications, no significant difference in early and long-term outcomes was identified between groups. Addition of CABG to AVR was not an independent risk factor for 30-day mortality, in-hospital MACCE, or long-term survival.

Increased life expectancy, combined with improved surgical techniques and postoperative care, has progressively expanded the criteria of cardiac surgery operability in the elderly. Almost half of the elderly patients with surgical aortic valve disease have associated coronary artery disease. The growth of minimally invasive techniques has made treatment choices increasingly challenging \[[@CR5]\].

Multiple studies have confirmed that isolated AVR can be performed with good outcomes in terms of early and late mortality and morbidity in the elderly \[[@CR5], [@CR23], [@CR24]\]. Furthermore, minimally invasive AVR can be achieved in elderly patients with satisfactory early and mid-term results \[[@CR25], [@CR26]\]. Results after combined CABG + AVR in the elderly population remain unclear. Various reports have suggested iAVR in the elderly to be associated with lower risk than AVR combined with CABG \[[@CR11], [@CR27], [@CR28]\]

Recent data from the German Aortic Valve Registry reported \[[@CR14]\] encouraging in-hospital mortality of 2.3% in 5738 patients over 75 years who underwent isolated AVR compared to 3.6% for AVR + CABG in the same age group. They observed low overall complication rates and good 1-year survival for all risk groups of patients, corroborating that conventional surgical AVR, with or without CABG, remains the gold standard for patients at low and intermediate risk.

In this study, 30-day in-hospital mortality was not statistically different between iAVR and AVR + CABG (4.5% and 6.5%, respectively; *p* = 0.38). These results are consistent with previous studies comparing both treatments that reported in-hospital mortality in iAVR ranging from 0 to 7.6% and AVR + CABG ranging from 1.9 to 11.5% \[[@CR9], [@CR13]--[@CR15], [@CR17], [@CR19], [@CR21], [@CR29], [@CR30]\].

Our data show that CABG combined with AVR can be safely performed without increasing operative mortality. Multivariate logistic regression of 30-day mortality found preoperative comorbidity such as EuroSCORE II, and postoperative complications such as stroke, low cardiac output and mechanical ventilation more than 48 h, as independent predictors of in-hospital mortality. The model revealed some predictors such as low cardiac output and mechanical ventilation more than 48 h which are well-known risk factors for early death.

CPB time and X-Clamp duration were statistically different between groups as expected, higher in AVR + CABG than iAVR subjects. These same differences are reported in other studies. Longer duration of CPB and X-Clamp are always a concern, particularly in the elderly, as longer CPB is associated with increased incidence of cerebral, renal and coagulation damage, and greater X-Clamp predisposes to increased risk of myocardial damage. Cappabianca \[[@CR16]\] reported that the duration of CPB time (OR 1.02, *p* = 0.004) was an independent predictor of in-hospital mortality, while Dell'Amore \[[@CR19]\] observed that a shorter X-Clamp time had a protective role (OR 0.8, *p* = 0.01).

In this study, both CPB and X-Clamp times were not associated with increased 30-day surgical mortality. Superior biocompatible material technology for CPB and improved myocardial protection are advances that permit long and complex cardiac operations, even in very elderly patients. We advocate complete myocardial revascularization as paramount to achieving good results and optimizing perioperative care.

Our reported 30-day mortality for iAVR (4.5%) and AVR + CABG (6.5%) are lower than in-hospital mortality reported by other investigators during the last decade \[[@CR10], [@CR11], [@CR16], [@CR29]\].

The most frequent postoperative complication observed was new-onset atrial fibrillation (NOAF). The overall rate was 45.5%, similar between the iAVR and AVR + CABG groups (47.5% vs 43.6%, respectively; *p* = 0.42). New-onset AF was not associated with 30-day mortality. Most cases of postoperative NOAF converted to sinus rhythm after medical treatment with amiodarone or with electrical cardioversion (6.4%). Among patients with postoperative NOAF, only 31 (7.7%) were discharged with permanent atrial fibrillation.

Long-term survival reported in our study is one of the longest follow-ups (up to 16 years) described in the literature for elderly patients (≥ 75 years) who underwent iAVR or combined AVR + CABG. Survival at 1, 5 and 10 years was 94.7 ± 1.6%, 72.6 ± 3.6% and 31.7 ± 4.8% for iAVR and 89.1 ± 2.3%, 73.9 ± 3.5% and 37.2 ± 4.8% for AVR + CABG patients. There is no statistical difference in survival curves between the two groups. These survival rates are comparable with previous reports \[[@CR9], [@CR18]--[@CR20]\], and good long-term survival is evident despite advanced age.

Cox regression multivariate analysis demonstrated that factors such as creatinine blood level, creatinine clearance ≤ 50 ml/min, COPD and NYHA class were independent predictors of late mortality \[[@CR31]\].

Noteworthy is the lack of statistical difference between iAVR and AVR + CABG with respect to long-term survival. This result is in line with other reports \[[@CR9], [@CR12], [@CR19]--[@CR21]\], but in contrast with the results described by Melby \[[@CR10]\] and Molstad \[[@CR32]\]. On one hand, Melby et al. observed that performing an AVR with concomitant CABG provided an improved long-term survival compared with isolated AVR (HR 0.7, 95% CI 0.47--0.96; *p* = 0.020). On the other side, Molstad and colleagues reported a detrimental effect of concurrent CABG at the time of AVR surgery compared to patients who underwent iAVR on long-term survival (HR 1.37, 95% CI 1.08--1.73; *p* = 0.02).

We found addition of CABG at the time of AVR was not associated with increased mortality in the unadjusted (HR 0.99; 95% CI 0.74--1.33; *p* = 0.99) and adjusted analysis (HR 0.83; 95% CI 0.59--1.17; *p* = 0.30). Surgical revascularization improves myocardial metabolism and reduces the risk of ischemia in hypertrophied left ventricles suggesting that CABG combined with AVR should be performed when indicated even in the elderly, without increasing operative risk.

In our study population, propensity matching provides an opportunity to compare the outcomes of patients with iAVR with those of patients with AVR + CABG and otherwise similar non-CAD comorbidity profiles. Matched and unmatched survival curves had similar trend, suggesting that CABG at the time of AVR neutralizes the adverse effects of coronary disease, provided that ischemic myocardial damage has not occurred after the operation. However, this data should be considered with caution because propensity score matching selected 276 subjects among 402 patients (68.6%), meaning that the best and the worst patients might have been excluded from the PSM analysis.

TAVI has been dramatically increased during the last decade \[[@CR7]\] and, recently, indication of TAVI has expanded to nonagenarians \[[@CR33]\] and even to intermediate-risk patients \[[@CR34]\]. In a recent meta-analysis, Biancari et al. \[[@CR33]\] reported a 30-day mortality of 7.1% and an excellent mid-term survival of 61.3% at 3 years in a pool of 1227 nonagenarians who underwent TAVI, while Thourani et al. \[[@CR34]\] reported a 30-day mortality of 1.1% and low incidence of mortality, stroke and aortic regurgitation at 1 year in a population of 1077 intermediate-risk patients. TAVI is now considered the first treatment of choice for high-risk and elderly patients. However, patients with TAVI indications need to be carefully selected because of some anatomical reasons, such as low take-off of coronary ostia, aggressive peripheral arteriopathy and left ventricular obstruction or calcification, which may severely compromise the immediate results. Moreover, the valve-in-valve option has considerable limitations in patients with small bioprosthetic valve and is not indicated in patients with a mechanical valve \[[@CR35]\]. Compared with TAVI, the surgical approach has the advantage of removing the calcified native valve, making a careful debridement of the aortic annulus and sizing appropriately the prosthesis valve. These factors may contribute to reducing the risk of paravalvular leak, PPM and requirement of permanent pacemaker. A controversial topic concerns the short and mid-term results of those patients who underwent TAVI + PCI compared to patients undergoing CABG + AVR. Despite that isolated TAVI proved firstly to have better results in those patients without previous CABG compared to patients with previous CABG \[[@CR36]\] and secondly to be superior compared to patients who underwent TAVI + PCI \[[@CR37]\], the evidence of a superiority of the TAVI + PCI compared to CABG + AVR is still very controversial and few studies have investigated it so far. Wendt et al. \[[@CR38]\] reported comparable results in high-risk patients undergoing either TAVI + PCI or AVR + CABG showing a 30-day mortality rate of 11.9% vs 12.5% (*p* = 0.89), respectively, and a 4-year survival of 53% and by 60.7% (*p* = 0.191), respectively. Similar results have recently been reported by Barbanti et al. \[[@CR39]\] in a retrospective study of intermediate-risk population. A more recent prospective randomized study (SURTAVI trial) \[[@CR40]\] showed acceptable and comparable results among intermediate-risk patients who underwent either TAVI + PCI or CABG + AVR in terms of all-cause mortality and disabling stroke at 2 years (16%, vs 14%, *p* = 0.69, respectively).

Our results showed a moderate discrimination power and a good calibration for 30-day mortality of EuroSCORE II. Conflicting results have been reported for EuroSCORE II to overestimate \[[@CR41]\] and underestimate the risks \[[@CR42]\]. Therefore, we can only recognize that the accuracy of the model is validated in our study population and we must be extremely cautious in stating that our discrimination and calibration analysis is better or worse than others already reported in the literature.

Study limitations {#Sec10}
=================

This study is limited in its retrospective nature. Moreover, this is a single-centre study with a relatively small sample size analysed in a long period. We know that this limitation may be as cause of preoperative surgical selection bias due to the change over the study period of cardiologist's referral, the surgeon's decision to operate some elderly patients and the development of TAVI techniques.

Since the beginning of TAVI program in 2009 in our institution, patients older than 80 years with high operative risk (EuroSCORE II \> 15%), patients with high grade of frailty and patients who refused the conventional surgical approach were directed to the TAVI strategy. This has obviously changed the characteristics of our cohort study during the last decade, creating bias in patient selection.

Patients older than 75 years may be affected by different grades of frailty. Unfortunately, we could not account for this variable that may affect the early and long-term results and can be one more factor causing preoperative surgical selection bias.

Another limitation relates to the long-term follow-up, which is restricted only to the all-cause death.

Conclusions {#Sec11}
===========

This study represents one of the longest reported follow-up periods for iAVR and AVR + CABG in elderly patients. Although patients over 75 years of age underwent combined surgical myocardial revascularization and AVR had higher incidence of early complications, this treatment does not represent a prohibitive surgical risk in this population. Long-term outcomes are comparable to elderly patients who underwent isolated aortic valve replacement.
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